Royalty Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Royalty Pharma wird ein jährliches Gewinn- und Umsatzwachstum von 12.5% bzw. 8.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 25.8% betragen.

Wichtige Informationen

12.5%

Wachstumsrate der Gewinne

13.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	8.4%
Zukünftige Eigenkapitalrendite	25.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	21 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12

Recent updates

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Apr 28

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Apr 25

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Royalty Pharma declares $0.19 dividend

Jul 15

Royalty Pharma: Unique Diversification, Bear Market Performer

May 26

The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Apr 25

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:RPRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,211	1,274	2,213	2,847	6
12/31/2025	2,927	1,097	1,935	2,566	6
12/31/2024	2,643	942	2,325	2,203	6
3/31/2024	2,239	799	1,019	2,619	N/A
12/31/2023	2,355	1,135	872	2,988	N/A
9/30/2023	2,324	184	1,422	2,785	N/A
6/30/2023	2,361	255	522	2,750	N/A
3/31/2023	2,359	332	374	2,718	N/A
12/31/2022	2,237	43	402	2,144	N/A
9/30/2022	2,247	507	401	2,064	N/A
6/30/2022	2,259	466	312	1,995	N/A
3/31/2022	2,278	602	263	1,952	N/A
12/31/2021	2,289	620	-174	2,018	N/A
9/30/2021	2,286	783	-732	2,093	N/A
6/30/2021	2,239	972	-159	2,132	N/A
3/31/2021	2,195	493	-496	2,090	N/A
12/31/2020	2,122	495	-148	2,035	N/A
9/30/2020	2,008	1,745	104	1,947	N/A
6/30/2020	1,934	1,863	793	1,858	N/A
3/31/2020	1,880	2,052	1,093	1,705	N/A
12/31/2019	1,814	2,349	-54	1,667	N/A
12/31/2018	1,795	1,378	1,349	1,618	N/A
12/31/2017	1,598	1,210	N/A	1,418	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RPRXDas prognostizierte Gewinnwachstum (12.5% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: RPRXDie Erträge des Unternehmens (12.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: RPRXDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: RPRXDie Einnahmen des Unternehmens (8.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: RPRXDie Einnahmen des Unternehmens (8.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RPRXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (25.8%)

Royalty Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 10%

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Consensus EPS estimates increase by 79%

Consensus EPS estimates increase by 68%

Consensus EPS estimates increase by 94%

Consensus EPS estimates increase by 55%

Recent updates

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Consensus EPS estimates fall by 10%

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)

Upcoming dividend of US$0.21 per share

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Fourth quarter dividend of US$0.21 announced

Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 79%

Royalty Pharma: Solid Operational Performance

Full year 2023 earnings released: EPS: US$2.54 (vs US$0.098 in FY 2022)

Upcoming dividend of US$0.21 per share at 2.9% yield

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024

Consensus EPS estimates increase by 68%

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Director recently sold US$19m worth of stock

Director notifies of intention to sell stock

Consensus EPS estimates increase by 94%

Third quarter 2023 earnings released: EPS: US$0.16 (vs US$0.33 in 3Q 2022)

Upcoming dividend of US$0.20 per share at 2.9% yield

Consensus EPS estimates increase by 55%

Consensus EPS estimates increase by 15%

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Upcoming dividend of US$0.20 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Founder recently bought US$3.8m worth of stock

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Insider recently sold US$6.5m worth of stock

Insider notifies of intention to sell stock

Director notifies of intention to sell stock

Founder recently bought US$7.7m worth of stock

Consensus EPS estimates increase by 243%

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of US$0.20 per share at 2.4% yield

First quarter 2023 earnings released: EPS: US$0.77 (vs US$0.12 in 1Q 2022)

Consensus EPS estimates increase by 46%

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Director recently sold US$5.1m worth of stock

Insider recently sold US$932k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.20 per share at 2.1% yield

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma plc to Report Q4, 2022 Results on Feb 15, 2023

Consensus forecasts updated

Royalty Pharma Declares First Quarter 2023 Dividend, Payable on March 15, 2023

Royalty Pharma Announces Expansion of Senior Leadership Team

Director recently sold US$2.5m worth of stock

Director recently sold US$16m worth of stock

Director notifies of intention to sell stock

Director recently sold US$5.1m worth of stock

Consensus forecasts updated